<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00281710</url>
  </required_header>
  <id_info>
    <org_study_id>MED.RES.HOS.2005.02.TGK</org_study_id>
    <nct_id>NCT00281710</nct_id>
  </id_info>
  <brief_title>Urinary Aquaporin 2 Excretion After Methylprednisolone in Fasting Healthy Humans</brief_title>
  <official_title>Urinary Aquaporin 2 Excretion After Methylprednisolone in Fasting Healthy Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regional Hospital Holstebro</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regional Hospital Holstebro</source>
  <brief_summary>
    <textblock>
      We wanted to test the hypotheses that methylprednisolone up regulates u-AQP-2 in fasting&#xD;
      healthy humans&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">February 2007</completion_date>
  <primary_completion_date type="Actual">February 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Single</masking>
  </study_design_info>
  <primary_outcome>
    <measure>u-AQP-2</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>FeNa+</measure>
  </primary_outcome>
  <enrollment>20</enrollment>
  <condition>Healthy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  (1) Genders; both mal and female&#xD;
&#xD;
          -  (2) Age; 18- 65 years old&#xD;
&#xD;
          -  (3) BMI; below 30&#xD;
&#xD;
          -  (4) Females had to bee in oral contraceptive treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  (1) Clinical signs or history of disease in the heart, lungs, kidneys or endocrine&#xD;
             organs&#xD;
&#xD;
          -  (2) Abnormal laboratory test (blood haemoglobin, white cell count, platelets, plasma&#xD;
             sodium, plasma potassium, plasma creatinine, plasma albumin, plasma bilirubin, plasma&#xD;
             alanine aminotransferase, plasma cholesterol and blood glucose)&#xD;
&#xD;
          -  (3) Albuminuria or glucosuria&#xD;
&#xD;
          -  (4) Cancer&#xD;
&#xD;
          -  (5) Arterial hypertension&#xD;
&#xD;
          -  (6) Alcohol abuse&#xD;
&#xD;
          -  (7) Use of tobacco&#xD;
&#xD;
          -  (8) Medical treatment, except oral contraceptives&#xD;
&#xD;
          -  (9) Pregnancy or breast feeding&#xD;
&#xD;
          -  (10) Medicine abuse&#xD;
&#xD;
          -  (11) Donation of blood less than 1 month before the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erling B Pedersen, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Holstebro Hospital, 7500 Holstebro, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas G Knudsen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Holstebro Sygehus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Medicine, Holstebro Hospital</name>
      <address>
        <city>Holstebro</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>May 2008</verification_date>
  <study_first_submitted>January 23, 2006</study_first_submitted>
  <study_first_submitted_qc>January 23, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2006</study_first_posted>
  <last_update_submitted>May 6, 2008</last_update_submitted>
  <last_update_submitted_qc>May 6, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 9, 2008</last_update_posted>
  <keyword>AQP-2</keyword>
  <keyword>Methylprednisolone</keyword>
  <keyword>Urinary concentrating ability</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

